Steven Grover on The Role of FXII in the Pathogenesis of VTE
Steven Grover, Staff Scientist II at Beth Israel Deaconess Medical Center, shared on LinkedIn:
”Evidence for a role of coagulation factor FXII in the pathogenesis of venous thromboembolism has proven elusive to date.
In work led by Amelia Haj from Tem Bendapudi’s group we show that germline heterozygous loss of function in FXII is associated with a significantly reduced risk of venous thromboembolism.
A 50% reduction in plasma FXII levels, although unremarkable in the classical activated partial thromboplastin time assay, is sufficient to significantly reduce plasma thrombin generation by calibrated automated thrombography and venous thrombosis in a preclinical model.
Delighted to have been involved in this important work alongside several researchers from the Blood Research Center at UNC, Beth Israel Deaconess Medical Center and Massachusetts General Hospital.
The paper is out now in Springer Nature journal Nature Communications, read it here”
Article: Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis
Authors: Amelia K. Haj, David S. Paul, Sean J. Jurgens, Harish Eswaran, Lu-Chen Weng, Justine Ryu, Alfonso Rodriguez Espada, Sharjeel Chaudhry, Louis M. Feingold, Kristen Burke, Satoshi Koyama, Xin Wang, Joyce Francis, Seung Hoan Choi, Nigel Mackman, Wolfgang Bergmeier, Alex Burgin, Joel T. Rämö, Patrick T. Ellinor, Steven Grover, Pavan K. Bendapudi
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 13, 2025, 09:54Cihan Ay: ISTH 2026 In Planning!
-
Sep 12, 2025, 06:39Chokri Ben Lamine: Approach to Intra-Operative Bleeding in G6P Deficiency – Key Causes and Management
-
Sep 12, 2025, 05:33Rafael Gomes Highlights Key ESC 2025 CABG Findings: Aspirin Monotherapy Still Best After Surgery
-
Sep 14, 2025, 04:16F8 Gene Variants Affect Desmopressin Response in Female Hemophilia A Carriers
-
Sep 13, 2025, 10:36Drug-Induced Immune Haemolytic Anaemia: A Decade Review by Abdul Mannan
-
Sep 13, 2025, 09:44Christelle Orlando: Type II Antithrombin Deficiency Frequently Underdiagnosed Due to Assay Limitations
-
Sep 13, 2025, 07:18Eric Topol Shares a Study on The Consequences of Our Pervasive Exposure to Micro- and Nanoplastics
-
Sep 13, 2025, 06:30Steven Grover on The Role of FXII in the Pathogenesis of VTE
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 14, 2025, 06:39Abdul Mannan on Factor VIII Aurora: First Natural Gain-of-Function Mutation in Haemophilia A
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 13, 2025, 06:49Emna Gouider Belhadjali on the Role of NMOs in Advocating for Equitable Access to Diagnosis for WGBDs
-
Sep 12, 2025, 09:30Arun V J Explains How Blood Donation Rules Differ Worldwide and Why Your Donation Saves Lives Everywhere